Skip to main content
. 2014 Jun 25;3(6):137–140. doi: 10.1002/cld.369

Figure 2.

Figure 2

SVR12 rates in phase 3 trials of AbbVie regimens of ABT‐450/ritonavir, Ombitasvir (ABT‐267) and Dasabuvir (ABT‐333) with or without ribavirin in patients with HCV genotype 1.9, 10, 11, 12 (A) Treatment‐naïve noncirrhotic patients: SAPPHIRE‐I (subtype 1a and 1b), PEARL‐IV (subtype 1a), and PEARL‐III (subtype 1a). (B) Treatment‐experienced, noncirrhotic patients: SAPPHIRE‐II (subtype 1a and 1b) and PEARL‐II (subtype 1b). (C) Treatment‐naïve and treatment‐experienced patients with cirrhosis (subtype 1a and 1b).